Repligen Completes Expansion of Manufacturing Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Repligen Completes Expansion of Manufacturing Facility



Repligen has completed a 9,000-ft2 expansion of its manufacturing facilities at its Waltham, Massachusetts’s headquarters. The production suite more than doubles capacity for Repligen’s OPUS line of prepacked chromatography columns, with cleanrooms built to ISO 7 specifications providing an appropriately controlled environment for GMP production.

The facility expansion also triples warehouse space and includes purification and fermentation laboratories for optimization of existing manufacturing processes, new product development, and applications support. An additional 17,000 ft2 of space is reserved for future expansion of the same facility.

Source: Repligen

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here